NCT07062887 Digital Mindfulness for Young Adults With Type 1 Diabetes
| NCT ID | NCT07062887 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yale University |
| Condition | Type 1 Diabetes (T1D) |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2026-02-04 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2026-02-04 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research study is to test a mindfulness app called Calm Health among young adults with type 1 diabetes or other absolute insulin deficiency diabetes. Mindfulness is the practice of being aware of your thoughts and feelings in the moment without judgment or negative reaction. All participants will receive mindfulness guidance and personalized feedback about the relationship among your mindfulness, blood sugar, stress, and sleep.
Eligibility Criteria
Inclusion Criteria: 1. Receiving diabetes care at Yale New Haven Children's Hospital or Yale New Haven Hospital. 2. Sign and date informed consent form we will provide 3. Willingness to complete procedures and availability for duration of the study 4. Aged 18-30 years 5. Diagnosed with type 1 diabetes (T1D) or other absolute insulin deficiency diabetes (latent autoimmune diabetes of adulthood, diabetes secondary to pancreatitis) for at least 1 year. 6. User of a continuous glucose monitor (CGM) in your routine clinical care for at least the past 2 weeks. 7. Able to use a smartphone. 8. Able to read and write English. Exclusion Criteria: 1. Current meditation or mindfulness practice meeting or exceeding the study's recommended schedule 2. Current severe untreated psychiatric illness (e.g., bipolar disorder, schizophrenia, major depression, panic disorder, borderline personality disorder, organic mood or mental disorders) or active suicidal ideation 3. New or unstable psychopharmaceutical treatment in past 2 months. 4. Current or planned pregnancy during study period.
Contact & Investigator
Laura M Nally, MD
PRINCIPAL INVESTIGATOR
Yale University
Frequently Asked Questions
Who can join the NCT07062887 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 30 Years, studying Type 1 Diabetes (T1D). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07062887 currently recruiting?
Yes, NCT07062887 is actively recruiting participants. Contact the research team at laura.nally@yale.edu for enrollment information.
Where is the NCT07062887 trial being conducted?
This trial is being conducted at New Haven, United States.
Who is sponsoring the NCT07062887 clinical trial?
NCT07062887 is sponsored by Yale University. The principal investigator is Laura M Nally, MD at Yale University. The trial plans to enroll 10 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.